
LENSAR Inc
NASDAQ:LNSR

Operating Margin
LENSAR Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
![]() |
LENSAR Inc
NASDAQ:LNSR
|
154.1m USD |
-24%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
215.3B USD |
18%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
180.6B USD |
28%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
159.3B USD |
19%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
151.9B USD |
22%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
117.2B USD |
20%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
52.1B EUR |
14%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
52B USD |
13%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
45.3B USD |
28%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
43.3B USD |
29%
|
|
US |
![]() |
Resmed Inc
NYSE:RMD
|
39.8B USD |
32%
|
LENSAR Inc
Glance View
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 110 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The company is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on LENSAR Inc's most recent financial statements, the company has Operating Margin of -23.8%.